key: cord-0843700-nv8jwbrh
authors: Napoli, Claudio; Donatelli, Francesco; Maiello, Ciro
title: In Situ Immune Profiling Identifies Immune Players Involved in Allograft Rejection: A Call for Precision Medicine
date: 2020-07-27
journal: JACC Basic Transl Sci
DOI: 10.1016/j.jacbts.2020.05.012
sha: ea58ba1026414335f0893cebcc1aa859f8c9b6fd
doc_id: 843700
cord_uid: nv8jwbrh

nan

In Situ Immune Profiling Identifies Immune Players Involved in Allograft Rejection

We read with interest about the use of quantitative multiplex immunofluorescence (QmIF) methodology 

Situ immune profiling of heart transplant biopsies improves diagnostic accuracy and rejection risk stratification

Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection

Allograft rejection of ISHLT grade $3A occurring late after heart transplantation-a distinct entity?

Effect on long-term mortality of HLA-DR matching in heart transplantation

Fluid-based assays and precision medicine of cardiovascular diseases: the "hope" for Pandora's box?

Feldman is an equity holder and has technology licensed to both Elucid Bioimaging and Inspirata; and is a consultant for Inspirata, Phillips Healthcare, XFIN, and Virbio; and is a member of the advisory board of Inspirata. Dr. Feldman is a consultant for Phillips Healthcare, XFIN, and Virbio. Dr. Margulies has received research grants from Sanofi-Aventis USA and GlaxoSmithKline; and is a consultant for and an advisory board member for Pfizer and MyoKardia.The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.